Should CRISPR-Cas9 Be Used in Human Embryos to Eliminate Genetic Diseases? Public Attitudes and Benefit–Risk Analysis
DOI:
https://doi.org/10.61173/as39n470Keywords:
CRISPR-Cas9, human embryos, genetic disease, public opinion, probabilistic modelling, bioethicsAbstract
CRISPR-Cas9 is one of the most extraordinary biotechnologies of the twenty-first century, and its possible application to editing human embryos to cure hereditary diseases still brings up some ethical, social, and technical questions. The current research examines the survey-based public perceptions and probabilistic benefits and risks trades-offs using a mixture of the primary survey data and mathematical model. A questionnaire that was structured and given to 320 participants; mostly students aged 16 and above, was used to measure demographic variables, risk perception, and trust in science and support of CRISPR in the event of severe disease, mild disease, and enhancement. It was found that there was high ranking of acceptance with the strongest support going to the severe cases of therapeutic application, moderate to mild disease cases having moderate and slight support respectively and enhancement hardly receiving support. The results of statistical testing proved the significant difference between severe disease and enhancement support. Contrary to the expectations, risk perception was not a significant predictor of support and such a result suggests that the aspect of humanitarian may override the aspect of technical in the sampled population. Probabilistic modelling of cystic fibrosis and Huntington’s disease demonstrated that expected net benefits remained positive across reported ranges of editing efficiency and off-target probabilities, with high-burden diseases offering substantially greater margins of acceptable risk. Demographic variables, including age, field of study, and prior knowledge, were not significant predictors of support, suggesting that ethical reasoning exerts more influence than background characteristics. The findings provide evidence that therapeutic necessity dominates public acceptance of embryo editing among the sampled academic population and that quantitative models can reinforce the case for carefully regulated medical applications. Limitations include the use of a nonrepresentative sample, primarily students, which may not fully reflect broader public attitudes.
References
Decker, S. S. (2025). Navigating the ethical implications of human gene editing technology: A comparative, multi-perspective approach. [PhD Thesis]. https:// baylor-ir.tdl.org/items/acb12778-d2da-4040-81e8-7baf69e1addc Dean&Francis ISSN 2959-409X Foley, R. A., Sims, R. A., Duggan, E. C., Olmedo, J. K.,
Ma, R., & Jonas, S. J. (2022). Delivering the CRISPR/ Cas9 system for engineering gene therapies: Recent cargo and delivery approaches for clinical translation. Frontiers in Bioengineering and Biotechnology, 10, 973326.
Gibelli, F., Ricci, G., & Bailo, P. (2025). Genome Editing in Medicine: A Scoping Review of Ethical, Bioethical, and Medico-Legal Implications. Journal of Law, Medicine & Ethics, 1–9. Giuliano, R., Maione, A., Vallefuoco, A., Sorrentino, U., & Zuccarello, D. (2023). Preimplantation genetic testing for genetic diseases: Limits and review of current literature. Genes, 14(11), 2095. Gowen, B. G., Melton, K., Leong, W. I., Khekare, P., Mc- Cawley, S., Chan, J., Boivin, P., Jani, V., Cantor, A. J., &
Tambe, A. (2025). Systematic identification and characterization of high efficiency Cas9 guide RNAs for therapeutic targeting of ADAR. PloS One, 20(2), e0317745. Hallerman, E., Bredlau, J., Camargo, L. S. A., Dagli, M. L. Z., Karembu, M., Kovich, D., Muia, A. N., Murrone, M. L., Rocha-Salavarrieta, P. J., Romero-Aldemita, R., Tiz-
ard, M., Walton, M., & Wray-Cahen, D. (2024). Enabling regulatory policy globally will promote realization of the potential of animal biotechnology. CABI Agriculture and Bioscience, 25. https://doi.org/10.1186/s43170-024- 00221-6
Himes, D. (2025). Ethical Leadership in the Development and Integration of AI Implants for Human Enhancement [PhD Thesis, Alliant International University]. https:// search.proquest.com/openview/2c6278aeebbfd6ef70020f- 6ecd04dc03/1?pq-origsite=gscholar&cbl=18750&diss=y
Kansal, R. (2024). The CRISPR-Cas system and clinical applications of CRISPR-based gene editing in hematology with a focus on inherited germline predisposition to hematologic malignancies. Genes, 15(7), 863.
Kim, H. K., & Kim, H. H. (2025). Evaluation and prediction of guide RNA activities in genome-editing tools. Nature Reviews Bioengineering, 1–16.
Konishi, C. T., & Long, C. (2020). Progress and challenges in CRISPR-mediated therapeutic genome editing for monogenic diseases. Journal of Biomedical Research, 35(2), 148.
Li, R.-Y., & Ma, Y.-Y. (2024). Knowledge and Attitudes toward Biotechnology in STEM Education as an Indicator of Scientific Literacy. Journal of Baltic Science Education, 23(1), 76–89.
Lopes, R., & Prasad, M. K. (2024). Beyond the promise: Evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Frontiers in Bioengineering and Biotechnology, 11, 1339189.
Montenegro de Wit, M. (2020). Democratizing CRISPR? Stories, practices, and politics of science and governance on the agricultural gene editing frontier. Elem Sci Anth, 8, 9.
Musson, R., Gąsior, Ł., Bisogno, S., & Ptak, G. E. (2022). DNA damage in preimplantation embryos and gametes: Specification, clinical relevance and repair strategies. Human Reproduction Update, 28(3), 376–399.
Nielsen, J., Eckstein, L., Nicol, D., & Stewart, C. (2021). Integrating public participation, transparency and accountability into governance of marketing authorisation for genome editing products. Frontiers in Political Science, 3, 747838. Nordberg, A., Minssen, T., Feeney, O., De Miguel Beri-
ain, I., Galvagni, L., & Wartiovaara, K. (2020). Regulating germline editing in assisted reproductive technology: An EU cross‐disciplinary perspective. Bioethics, 34(1), 16–32. https://doi.org/10.1111/bioe.12705
Rosanwo, T. O., & Bauer, D. E. (2021). Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy. Molecular Therapy, 29(11), 3163– 3178.
Saul, N. (2025). Anthropotechnik? Ernst Jünger’s Organic Constructions, Self-Optimization and Modernity. Self-Optimization in Modernist Culture, 9, 328.
Stevens, I., & Gilbert, F. (2022). International Regulatory Standards for the Qualitative Measurement of Deep Brain Stimulation in Clinical Research. Journal of Empirical Research on Human Research Ethics, 17(3), 228–241. https://doi.org/10.1177/15562646221094922
Tasnim, N. (2024). Understanding the impacts of biotechnology: A survey among the university students in chittagong [PhD Thesis, Brac University]. https://dspace. bracu.ac.bd/xmlui/handle/10361/23987
Wismayer, H. (2022). A Heuristic Inquiry in Two Parts Exploring Experiences of Silence Described by Novice and Clinically-experienced Psychotherapists and Any Implications for the Therapeutic Encounter [PhD Thesis, University of Roehampton]. https://pure.roehampton. ac.uk/ws/portalfiles/portal/8557828/Wismayer_Hildegard_Final_Thesis.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2026 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
